Krka, D.d., Novo Mesto

Krka, d. d., Novo Mesto, established on April 23, 1954, is a Slovenian multinational pharmaceutical company headquartered in Novo Mesto, Slovenia. The company specializes in the development, production, and marketing of generic pharmaceuticals, non-prescription products, and animal health products. Its product portfolio spans various therapeutic areas, including cardiovascular, gastrointestinal, central nervous system, oncology, pain relief, and anti-infectives. Krka markets its products under numerous brand names, such as Atoris, Roswera, Ampril, Lorista, and Nolpaza. (krka.biz)

In 2023, Krka reported total sales of €1.806 billion, underscoring its significant presence in the global pharmaceutical market. The company employs over 12,500 individuals and operates in more than 70 countries worldwide. Its production facilities are located in Slovenia, with subsidiaries in the Russian Federation, Poland, Croatia, and Germany. Additionally, Krka has a joint venture in China, reflecting its expansive international footprint. (krka.biz)

Krka's distribution network is extensive, encompassing both domestic and international markets. Within Slovenia, the company operates multiple production sites, including those in Ločna and Bršljin (both in Novo Mesto), Krško, Šentjernej, and Ljutomer. These facilities are strategically located to facilitate efficient distribution across the country. Internationally, Krka's subsidiaries and joint ventures in the Russian Federation, Poland, Croatia, Germany, and China play a crucial role in the company's distribution strategy, ensuring a robust supply chain that caters to a diverse global clientele. (krka.biz)

Krka, d. d., Novo Mesto holds a prominent position in Slovenia's pharmaceutical supply chain as a primary wholesaler and distributor. The company's extensive product range and established market presence enable it to serve a wide array of healthcare providers, including hospitals, clinics, and pharmacies. Krka's role extends beyond distribution, as it also engages in the development and manufacturing of pharmaceutical products, positioning itself as a key player in both the production and supply of medicines within Slovenia and internationally. (krka.biz)

Krka's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from India. Between 2022 and 2026, the company imported finished pharmaceutical formulations valued at $14.3 million USD from India, encompassing 287 shipments and 413 unique formulations. The top five products imported include Naproxen ($12.7 million, 88.5% share), Clopidogrel ($1.3 million, 9.1% share), and Sitagliptin ($350,000, 2.4% share). This concentration indicates a strategic reliance on Indian suppliers for key therapeutic areas, particularly in analgesics and antipyretics.

The primary suppliers from India are UNICHEM LABORATORIES LIMITED, MICRO LABS LIMITED, and LAURUS LABS LIMITED, accounting for 57.2%, 32.8%, and 7.9% of the total import value, respectively. This supplier concentration suggests a stable and established relationship between Krka and these Indian manufacturers. However, the heavy reliance on a limited number of suppliers may pose risks related to supply chain disruptions, pricing fluctuations, and geopolitical factors affecting trade relations.

Krka's supply chain resilience concerning its Indian imports appears robust, given the established relationships with key suppliers such as UNICHEM LABORATORIES LIMITED, MICRO LABS LIMITED, and LAURUS LABS LIMITED. The diversity of formulations—413 unique products—indicates a broad sourcing strategy that mitigates risks associated with single-product dependencies. However, the concentration of imports in specific therapeutic categories, notably analgesics and antipyretics, suggests that any disruptions in these product lines could impact Krka's ability to meet market demand.

To enhance supply chain resilience, Krka may consider diversifying its supplier base further, exploring alternative sourcing options, and establishing contingency plans to address potential disruptions. Additionally, maintaining strong relationships with existing suppliers and monitoring geopolitical developments that could affect trade routes and regulations is crucial for sustaining a reliable supply chain.

Krka's sourcing pattern, characterized by a high concentration of imports from Indian suppliers, positions the company competitively in the Slovenian pharmaceutical market, particularly in the analgesics and antipyretics segments. The established relationships with key Indian manufacturers likely contribute to favorable pricing and consistent product quality, enhancing Krka's market position.

For Indian exporters aiming to become alternative suppliers to Krka, understanding the company's specific product requirements, quality standards, and regulatory compliance expectations is essential. Demonstrating the ability to meet these criteria, along with offering competitive pricing and reliable delivery schedules, can facilitate entry into Krka's supply chain.

In Slovenia, the Agency for Medicinal Products and Medical Devices (JAZMP) serves as the primary regulatory authority overseeing the pharmaceutical sector. JAZMP is responsible for the evaluation, approval, and monitoring of medicinal products, ensuring they meet the required safety, efficacy, and quality standards. The legislative framework governing pharmaceutical imports includes the Medicines Act, which outlines the procedures for marketing authorization, importation, and distribution of medicinal products.

For Indian generics to be marketed in Slovenia, they must undergo a centralized marketing authorization procedure through the European Medicines Agency (EMA). This process involves a comprehensive assessment of the medicinal product's quality, safety, and efficacy. Once approved by the EMA, the product can be marketed across all EU member states, including Slovenia. This centralized procedure streamlines the approval process for generics, facilitating their entry into the Slovenian market.

Import licensing in Slovenia is regulated by JAZMP, which ensures that all imported medicinal products comply with Slovenian and EU regulations. Importers must hold a valid wholesale distribution authorization issued by JAZMP, demonstrating their capability to handle pharmaceutical products responsibly. Additionally, Good Manufacturing Practice (GMP) certification is mandatory for all imported medicinal products. The EU recognizes GMP certificates from countries with equivalent standards, such as those issued by the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Therefore, Indian manufacturers seeking to export to Slovenia must ensure their facilities are GMP-compliant and hold the necessary certifications recognized by the EU.

Imported pharmaceutical products must undergo batch testing to verify their quality, safety, and efficacy. Stability studies are also required to ensure that products maintain their intended quality throughout their shelf life. Labeling requirements stipulate that product information be provided in Slovenian, including details such as the product name, active ingredients, dosage form, strength, and instructions for use. Serialization mandates are in place to prevent counterfeit products, requiring unique identifiers on packaging to track and trace products throughout the supply chain.

Between 2024 and 2026, Slovenia has implemented several regulatory changes affecting pharmaceutical imports. These include stricter requirements for GMP certification, enhanced batch testing protocols, and updated labeling standards to improve patient safety and product traceability. Additionally, Slovenia has aligned its import regulations more closely with EU directives, emphasizing the need for compliance with EU-wide standards for medicinal products. These changes aim to strengthen the quality assurance processes and ensure that imported pharmaceuticals meet the highest standards of safety and efficacy.

Krka's product strategy focuses on therapeutic areas with high market demand, particularly in analgesics and antipyretics, as evidenced by the significant import value of Naproxen. The company's emphasis on cardiovascular and diabetes medications aligns with global health trends, addressing prevalent conditions in the aging population. By concentrating on these therapeutic categories, Krka aims to meet the needs of a broad patient base, ensuring the availability of essential medicines in the Slovenian market.

Krka's sourcing strategy for generic drugs involves importing finished pharmaceutical formulations from established manufacturers in India. The company's preference for specific formulations, such as Naproxen, Clopidogrel, and Sitagliptin, indicates a targeted approach to procurement, focusing on high-demand products. India's well-established pharmaceutical industry, characterized by its compliance with international quality standards and competitive pricing, makes it a strategic partner for Krka's sourcing needs.

Krka serves multiple segments of the Slovenian pharmaceutical market, including retail pharmacies, hospitals, and government tenders. The company's diverse product portfolio enables it to cater to various healthcare providers, ensuring the availability of essential medicines across different channels. Krka's role as a primary wholesaler and distributor further solidifies its position in the Slovenian market, facilitating efficient supply chain management and product accessibility.

There is a realistic opportunity for new Indian suppliers to enter Krka's supply chain, particularly